在异基因干细胞移植受者中，抢先使用更昔洛韦（GCV）治疗后，未出现赋予GCV耐药性的巨细胞病毒UL97突变。
Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
作者信息
Gilbert C, Roy J, Belanger R, Delage R, Beliveau C, Demers C, Boivin G
机构信息
Research Center in Infectious Diseases of the Centre Hospitalier Universitaire de Québec and Department of Medical Biology, University de Montréal, Québec, Canada.
出版信息
Antimicrob Agents Chemother. 2001 Dec;45(12):3669-71. doi: 10.1128/AAC.45.12.3669-3671.2001.
Abstract
Fifty allogeneic stem cell transplant recipients were enrolled in a prospective cytomegalovirus pp65 antigenemia-guided preemptive therapy trial. Among these, 10 of 34 patients who received ganciclovir exhibited sustained and/or recurrent antigenemia despite treatment. Thirteen leukocyte preparations from these 10 subjects were screened for the presence of the most frequent cytomegalovirus UL97 mutations conferring ganciclovir resistance. None of these mutations were detected after mean and median ganciclovir exposures of 31.6 and 28.0 days, respectively.
摘要
五十名异基因干细胞移植受者参加了一项前瞻性巨细胞病毒pp65抗原血症指导的抢先治疗试验。其中，34名接受更昔洛韦治疗的患者中有10名尽管接受了治疗仍出现持续和/或复发性抗原血症。对这10名受试者的13份白细胞制剂进行筛查，以检测最常见的赋予更昔洛韦耐药性的巨细胞病毒UL97突变。在更昔洛韦平均暴露31.6天和中位数暴露28.0天后，均未检测到这些突变。
相似文献
1
Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.在异基因干细胞移植受者中，抢先使用更昔洛韦（GCV）治疗后，未出现赋予GCV耐药性的巨细胞病毒UL97突变。
Antimicrob Agents Chemother. 2001 Dec;45(12):3669-71. doi: 10.1128/AAC.45.12.3669-3671.2001.
2
Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.阿根廷免疫功能低下患者中与更昔洛韦耐药相关的巨细胞病毒UL97突变
J Clin Virol. 2004 Jul;30(3):271-5. doi: 10.1016/j.jcv.2003.11.003.
3
[Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].[初始巨细胞病毒病毒载量对异基因干细胞移植受者更昔洛韦抢先治疗疗效的影响]
Enferm Infecc Microbiol Clin. 2010 Jan;28(1):6-12. doi: 10.1016/j.eimc.2009.01.010. Epub 2009 May 1.
4
The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.在细胞相关蚀斑减少试验中，混合的人巨细胞病毒UL97野生型和突变株对更昔洛韦敏感性的影响。
J Clin Virol. 2004 May;30(1):50-6. doi: 10.1016/j.jcv.2003.08.010.
5
6
The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.肾移植受者中巨细胞病毒对更昔洛韦治疗产生耐药性的情况。
Int Immunopharmacol. 2006 Dec 20;6(13-14):2031-7. doi: 10.1016/j.intimp.2006.07.022. Epub 2006 Aug 8.
7
A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.一项随机试验，比较巨细胞病毒抗原血症检测与筛查支气管镜检查在异基因骨髓和外周血干细胞移植受者中早期检测和预防疾病的效果。
Bone Marrow Transplant. 2001 Sep;28(5):485-90. doi: 10.1038/sj.bmt.1703178.
8
9
Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain.异基因造血干细胞移植后耐更昔洛韦的巨细胞病毒疾病：通过体外选择UL97突变株进行表型诊断的陷阱
J Infect Dis. 2003 Jan 1;187(1):139-43. doi: 10.1086/346240. Epub 2002 Dec 13.
10
Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection.在接受伐昔洛韦预防治疗的活动性巨细胞病毒感染肾移植受者中检测更昔洛韦耐药性。
J Med Virol. 2004 Aug;73(4):566-73. doi: 10.1002/jmv.20127.
引用本文的文献
1
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后 CMV 再激活的治疗策略
Blood. 2020 May 7;135(19):1619-1629. doi: 10.1182/blood.2019000956.
2
Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.造血干细胞移植后的感染并发症：韩国的现状与未来展望
Korean J Intern Med. 2018 Mar;33(2):256-276. doi: 10.3904/kjim.2018.036. Epub 2018 Feb 27.
3
How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.我如何治疗造血细胞移植受者的难治性巨细胞病毒感染
Blood. 2016 Dec 8;128(23):2624-2636. doi: 10.1182/blood-2016-06-688432. Epub 2016 Oct 19.
4
Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.造血干细胞移植受者抢先性更昔洛韦治疗期间巨细胞病毒抗原血症的反常性升高：发生率、危险因素和临床结局。
J Clin Microbiol. 2011 Dec;49(12):4179-84. doi: 10.1128/JCM.05464-11. Epub 2011 Oct 26.
5
The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.人类巨细胞病毒抗性的遗传基础及抗病毒抗性分析的当前趋势。
Infect Disord Drug Targets. 2011 Oct;11(5):504-13. doi: 10.2174/187152611797636668.
6
The search for new therapies for human cytomegalovirus infections.寻找人类巨细胞病毒感染的新疗法。
Virus Res. 2011 May;157(2):212-21. doi: 10.1016/j.virusres.2010.11.004. Epub 2010 Nov 21.
7
Antiviral drug resistance of human cytomegalovirus.人巨细胞病毒的抗病毒药物耐药性。
Clin Microbiol Rev. 2010 Oct;23(4):689-712. doi: 10.1128/CMR.00009-10.
8
Human cytomegalovirus resistance to antiviral drugs.人巨细胞病毒对抗病毒药物的耐药性。
Antimicrob Agents Chemother. 2005 Mar;49(3):873-83. doi: 10.1128/AAC.49.3.873-883.2005.
9
Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.异基因干细胞移植受者巨细胞病毒病的预防
Clin Microbiol Rev. 2003 Oct;16(4):647-57. doi: 10.1128/CMR.16.4.647-657.2003.
10
High impact of an expanded restriction fragment length polymorphism assay on detection of ganciclovir-resistant UL97 mutants of human cytomegalovirus.扩展的限制性片段长度多态性分析对检测人巨细胞病毒更昔洛韦耐药UL97突变体的高影响
Antimicrob Agents Chemother. 2003 Jan;47(1):442-3. doi: 10.1128/AAC.47.1.442-443.2003.
本文引用的文献
1
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes.异基因造血干细胞移植后抢先抗巨细胞病毒治疗期间pp65抗原血症升高：危险因素、与DNA载量的相关性及预后
Blood. 2001 Feb 15;97(4):867-74. doi: 10.1182/blood.v97.4.867.
2
Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation.血液和骨髓同种异体移植后，使用pp65抗原血症检测法和COBAS AMPLICOR CMV MONITOR PCR检测法对巨细胞病毒（CMV）病毒血症进行定量分析。
J Clin Microbiol. 2000 Dec;38(12):4356-60. doi: 10.1128/JCM.38.12.4356-4360.2000.
3
4
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.实体器官移植受者中耐更昔洛韦巨细胞病毒疾病的出现。
Lancet. 2000 Aug 19;356(9230):645-9. doi: 10.1016/S0140-6736(00)02607-6.
5
Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.一名肾移植受者口服维持治疗后巨细胞病毒对更昔洛韦产生耐药性的情况
Transplantation. 2000 Jan 15;69(1):182-4. doi: 10.1097/00007890-200001150-00032.
6
The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.肺移植后耐更昔洛韦巨细胞病毒感染的影响
Transplantation. 1999 Nov 15;68(9):1272-9. doi: 10.1097/00007890-199911150-00010.
7
Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child.对UL97区域进行全面的限制性分析可在一名免疫功能低下儿童中早期检测出对更昔洛韦耐药的人巨细胞病毒。
J Infect Dis. 1999 Aug;180(2):491-5. doi: 10.1086/314877.
8
Resistance of human cytomegalovirus to antiviral drugs.人巨细胞病毒对抗病毒药物的耐药性。
Clin Microbiol Rev. 1999 Apr;12(2):286-97. doi: 10.1128/CMR.12.2.286.
9
Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy.巨细胞病毒UL97基因中的新型突变与对更昔洛韦治疗的耐药性相关。
Transplantation. 1999 Mar 15;67(5):755-7. doi: 10.1097/00007890-199903150-00020.
10
Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood.一名心脏移植受者血液中存在多种人巨细胞病毒毒株，口服更昔洛韦后出现更昔洛韦耐药。
Transplantation. 1998 Aug 15;66(3):324-9. doi: 10.1097/00007890-199808150-00008.
Zotero 插件